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Abstract
Background: We have previously demonstrated intrinsic anti-HIV activity in cervicovaginal lavage (CVL) from HIV-infected
women with high CD4 counts and not on antiretroviral therapy. However, the impact of HIV disease progression on CVL
innate immune responses has not been delineated.
Methods: CVL from 57 HIV-infected women not on antiretroviral therapy were collected by washing the cervicovaginal area
with 10 ml of sterile normal saline. We characterized subject HIV disease progression by CD4 count strata: .500 cells/ml,
200–500 cells/ml, or ,200 cells/ml of blood. To assess CVL anti-HIV activity, we incubated TZM-bl cells with HIV plus or minus
CVL. Antimicrobials, cytokines, chemokines and anti-gp160 HIV IgG antibodies were measured by ELISA and Luminex.
Results: CVL exhibited broad anti-HIV activity against multiple laboratory-adapted and transmitted/founder (T/F) viruses,
with anti-HIV activity ranging from 0 to 100% showing wide variation between viral strains. Although there was broad CVL
inhibition of most both laboratory-adapted and T/F virus strains, there was practically no inhibition of T/F strain RHPA.c,
which was isolated from a woman newly infected via heterosexual intercourse. HIV disease progression, measured by
declining CD4 T cell counts, resulted in a selective reduction in intrinsic anti-HIV activity in CVL that paralleled CVL decreases
in human beta-defensin 2 and increases in Elafin and secretory leukocyte protease inhibitor. HIV disease progress predicted
decreased CVL anti-HIV activity against both laboratory-adapted and T/F strains of HIV. Anti-HIV activity exhibited close
associations with CVL levels of fourteen cytokines and chemokines.
Conclusions: Amid a multifaceted immune defense against HIV-1 and other sexually transmitted pathogens, HIV disease
progression is associated with selective disturbances in both CVL anti-HIV activity and specific innate immune defenses in
the human female reproductive tract (FRT). Overall, these studies indicate that innate immune protection in the FRT is
compromised as women progress to AIDS.
Citation: Lahey T, Ghosh M, Fahey JV, Shen Z, Mukura LR, et al. (2012) Selective Impact of HIV Disease Progression on the Innate Immune System in the Human
Female Reproductive Tract. PLoS ONE 7(6): e38100. doi:10.1371/journal.pone.0038100
Editor: Rupert Kaul, University of Toronto, Canada
Received February 1, 2012; Accepted April 30, 2012; Published June 4, 2012
Copyright:  2012 Lahey et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health (NIH) Grants Allergy and Infectious Diseases AI51877 and AI13541 (CRW), AI40350 and
AI066884, (SCU), NIH Center for HIV/AIDS Vaccine Immunology U01-AI067854 (JCK and CO); Lifespan/Tufts/Brown Centers for AIDS Research (CFAR) P30AI42853,
Centers for Disease Control 106795 (SCU and KHM) and the Virology and Nucleotide Sequencing Cores of the University of Alabama at Birmingham CFAR (P30-
AI27767) NIH, National Center for Research Resources, Centers for Biomedical Research Excellence 5P20RR016437-08 (TL). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Timothy.Lahey@Dartmouth.edu
¤ Current address: Department of Epidemiology and Biostatistics, The George Washington University, Washington, District of Columbia, United States of America
. These authors contributed equally to this work.
Introduction
Despite the proven efficacy of condoms and antiretroviral
therapy in preventing HIV transmission [1,2,3], the continued
expansion of the worldwide HIV pandemic is driven predomi-
nantly by heterosexual HIV transmission [4]. The development of
new ways to prevent heterosexual HIV transmission thus remains
a global public health priority. A major obstacle to the
development of new approaches to preventing heterosexual
transmission of HIV is uncertainty regarding the mechanisms of
innate immune protection from heterosexual transmission of HIV
infection.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38100The FRT is home to a robust and interconnected network of
mucosal immune defenses that protect against the transmission of
HIV and other sexually transmitted infections [5]. In addition to a
protective layer of cervical mucous and an epithelial cell lining,
multiple immune cell types exist in the tissues of the FRT
including macrophages, dendritic cells, natural killer cells and
neutrophils [6]. These cells contribute to innate and antigen-
specific immune responses against sexually transmitted pathogens
that are distinct from immune responses measured in the gut and
in peripheral blood samples [7,8]. Within the FRT, cytokines,
chemokines, endogenous microbicides and antibodies constitute
the multifaceted layer of soluble innate immune protection against
HIV and other sexually transmitted [8].
We have previously shown that CVL samples from HIV(-) and
HIV-infected women with CD4+T cell counts greater than 500
have profound anti-HIV activity against a range of laboratory-
adapted viruses, as well as against transmitted/founder viruses [9].
We have also shown that CVL from HIV-infected women contain
multiple endogenous microbicides such as human beta defensin 2
(HBD2), Elafin, macrophage inflammatory protein-3 alpha (MIP-
3a) and secretory leukocyte protease inhibitor (SLPI) along with
HIV-specific IgG. As part of these studies, we found a correlation
between anti-HIV activity of CVL from HIV(2) and HIV-
infected women with HBD2 and MIP-3a as well as the levels of
CVL IgG directed at HIV gp160 [9]. However, the exact
functional contribution of these CVL immune responses remains
unclear, as does the impact of HIV disease progression on each of
these likely overlapping and interacting immune responses.
HIV disease progression is associated with generalized immu-
nodeficiency [10], chronic immune activation [11,12], deteriora-
tion of HIV-specific T cell responses [13,14], and higher
circulating HIV viral loads [15]. It is plausible therefore that
HIV disease progression results in damage to the innate and
adaptive immune responses in the FRT. Yet, although CVL HIV
viral load increases with HIV disease progression [16], the impact
of HIV disease progression on CVL innate immune responses and
anti-HIV activity is not known. Given that dysregulation and/or
loss of immune responses in the genital tract has the potential to
make women more prone to transmitting HIV, it is critical to
define the impact of HIV disease progression on innate immune
responses in the CVL.
We hypothesized that HIV disease progression attenuates both
the anti-HIV activity and protective immune responses within the
FRT. To address this hypothesis, we assessed the impact of HIV
disease progression on the anti-HIV activity and innate immune
responses of CVL from HIV-infected women.
Methods
Subject Recruitment
The 57 HIV-infected and sexually-abstinent women in this
study were recruited from The Immunology Center, Miriam
Hospital as a part of an observational study on HIV shedding in
women. CVL from 15 HIV-uninfected women were obtained
from the Rhode Island site (Miriam Hospital, Brown University,
Providence, RI) of the HIV Epidemiology Research (HER) study.
Studies were conducted according to the principles expressed in
the Declaration of Helsinki and was approved by the Miriam
Hospital Institutional Review Board (Brown University, Provi-
dence, RI) as well as the Dartmouth College Committee for the
Protection of Human Subjects (Hanover, NH). All patients
provided written informed consent for the collection of samples
and subsequent analysis.
HIV-infected Study Participants
Women were aged 38–49 years. Enrollment criteria included a
normal menstrual history, not on hormonal contraceptives, and no
exposure to antiretroviral (ARV) drugs. For disease progression
analyses, patients were categorized into three groups based on
CD4 T cell counts: .500 cells/ml, 200–500 cells/ml, and
,200 cells/ml. Participants agreed to undergo gynecologic assess-
ment, and were excluded for pregnancy, breastfeeding, meno-
pause, or inter-menstrual bleeding in the previous three months.
Additionally, women were excluded if they had douched, used any
vaginal products, or had sexual intercourse during the 48 hrs prior
to CVL collection. CVL was collected by gently washing the
cervicovaginal area with 10 ml of sterile normal saline (pH,7.2).
Following CVL collection, samples were centrifuged at 10,0006g
for 5 min after which supernatants and cell pellets were stored at
280uC until used. Women were tested for lower genital tract
infections including but not limited to bacterial vaginosis (BV),
Trichomonas vaginalis, Neisseria gonorrhea and Candida albicans.
HIV-uninfected Participants
Women were aged 24–34 years. CVL were collected using an
identical approach to that described above. Following CVL
collection, samples were immediately frozen at 280uC. At the
time of analysis, samples were thawed to room temperature,
centrifuged at 10,0006g for 5 min after which supernatants were
assayed for anti-HIV activity. In preliminary studies (not shown),
we compared CVL that were centrifuged after collection and prior
to freezing with those that were freeze-thawed once prior to
centrifugation and found no differences in anti-HIV activity.
HIV Viral Stocks
Laboratory-adapted viral strains HIV-1 IIIB (X4) and BaL (R5)
were obtained from Dr. P. Gupta (University of Pittsburgh, PA).
Virus stocks produced in PBMC of molecularly cloned HIV-1
NL4.3 (X4; laboratory-adapted) and YU-2.c (R5; directly cloned
from brain tissue without culture were also used in this study [17]).
Also used was a PBMC-derived virus stock of CH077.c, CH058.c,
and RHPA.c, all sexually transmitted Clade B infectious molecular
clones (IMC) [18,19,20] matching the inferred T/F virus
nucleotide sequence from subjects 700010077, 700010058, and
RHPA4259 respectively. The RHPA.c is currently only available
full-length clade T/F IMC isolated from a heterosexually-infected
female subject. Virus stocks were propagated in PHA-stimulated
human PBMC and stored frozen at 280uC. Virus titers were
determined on TZM-bl cells as described [21].
Measurement of CVL Anti-HIV-1 Activity
Intrinsic anti-HIV activity in CVL was determined using TZM-
bl cells. The TZM-bl indicator cell line is a HeLa cell derivative
that expresses high levels of CD4, CCR5 and CXCR4 as well as
an HIV long terminal repeat (LTR)-driven b-galactosidase gene
plus firefly luciferase reporter cassettes that are activated by HIV
Tat protein expression and whose use has been standardized for
the measurement of HIV-1 infectivity by co-author J.C.K. [22,23].
TZM-bl cells were routinely sub-cultured every 3 to 4 days by
trypsinization and maintained in TZM-bl media consisting of
phenol red-free DMEM (Invitrogen Life Technologies, Carlsbad,
CA) supplemented with 10% defined FBS (HyClone, Logan, UT),
2 mM L-glutamine (Invitrogen Life Technologies), and 50 mg/ml
primocin (Invivogen, San Diego, CA).
TZM-bl cells were seeded at 2610
4 cells per well in a 96-well
microtiter plate and allowed to adhere overnight at 37uC. CVL
from individual patients were diluted 1:4 in TZM-bl media and
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for 1 hr at 37uC in a final volume of 100 ml. Following
incubation, media were aspirated from TZM-bl cells and the
virus plus CVL mixture (100 ml) was added to the cells along
with 100 ml of TZM-bl media. Luciferase activity was measured
on a luminometer after application of beta-Glo (Promega
Corporation, Madison, WI) per manufacturer’s instructions.
Controls included incubation of TZM-bl with virus alone, CVL
alone and cells in media. Uninfected cells and cells treated with
CVL alone were used to determine background luminescence
and data expressed in relative light units (RLU). To calculate
percent inhibition, the RLU values of ‘‘virus only’’ wells were
averaged and set to 100%. Values of CVL treated virus were
calculated as a percentage of the ‘‘virus only’’ and then
subtracted from 100 to calculate % inhibition. Viability of
TZM-bl cells upon treatment with CVL was quantified using
the CellTiter 96H AQueous One Solution Cell Proliferation
Assay (Promega) according to manufacturer’s instructions.
Briefly, reagent was added directly to cell cultures and
incubated for 30 min at 37uC followed by reading the plate
in a plate reader at OD 490 nm.
Measurement of Cytokines, Chemokines, Antimicrobials
in CVL
CVL supernatants were stored at –80uC until assayed for SLPI,
MIP-3a and Elafin with ELISA Quantikine kits or ELISA Duoset
kit from R&D Systems (Minneapolis, MN) according to the
manufacturer’s protocol. Standards for each ELISA were re-
suspended in phosphate buffered saline (PBS). CVL samples were
also diluted in 16PBS. Cytokines were quantified based on
standard curves obtained using an ELISA reader (Dynex,
Chantilly, VA). HBD2 was assayed with an ELISA test kit from
PeproTech (Rocky Hill, NJ) according to the manufacturer’s
protocol. For LUMINEX analyses, CVL were assayed for 14
different chemokines and cytokines (BioRad, Hercules, CA), as
previously described [24].
Measurement of Anti-gp160 HIV IgG Antibody Levels in
CVL
Specimens were tested by kinetic ELISA (kELISA) adapted
from an assay previously described for influenza [25]. The
kELISA measures substrate activation every 9 sec over the first
5 min of the enzymatic assay and plots the change in color per min
as mOD/min using a Thermomax microplate reader (Molecular
Devices, Sunnyvale, CA). Duplicate wells were coated with MN
strain gp160 (Protein Sciences, Meriden, CT). An uncoated well
was run with each sample to determine background, which was
subtracted from the result. A standard curve with a known positive
serum specimen was included in each assay as a measure of
sensitivity and reproducibility. Biotinylated anti-human IgG
conjugates were used with streptavidin-HRP and ABTS [25].
The presence of anti-HIV gp160 specific IgG antibodies used
15 m OD as a cut-off for detection.
Measurement of HIV-1 RNA in CVL and Plasma
Nucleic acid sequence-based amplification (BioMerieux, Dur-
ham, NC) was used to measure HIV-1 RNA as previously
described [26]. Briefly, we used a commercially available nucleic
acid sequence-based amplification assay (NASBA) technique for
quantification of HIV-1 RNA in paired plasma and cervico-
vaginal lavage samples (Organon Teknika Corp., Durham, NC).
This method is isothermal and amplifies only HIV-1 RNA and
not proviral DNA. Blood specimens were anti-coagulated in
ethylenediamine tetraacetic acid, and plasma was separated
within 1 hr of collection. An aliquot of 200 ml or 1 ml of
unfractionated cervicovaginal lavage was used for HIV-1 RNA
quantification. The plasma HIV-1 RNA viral load was
measured using 100 ml or 1 ml of plasma. Cervicovaginal
lavage and plasma were added to lysis buffer within 3 hr of
collection and stored at 270uC. Specimens were shipped in dry
ice to Massachusetts General Hospital, and stored at 270uC
until they were run for HIV-1 RNA testing. All results are
expressed as copies per ml.
Statistical Analysis
We contrasted CVL anti-HIV activity between CD4 count
strata using Kruskal-Wallis tests, and conducted two-group
comparisons using Mann-Whitney U tests, in both cases using a
P value significance threshold of less than 0.05. We measured the
association between CD4 count, PVL and GTVL with CVL anti-
HIV activity as well as CVL cytokine, chemokine and microbicide
levels using Spearman correlation coefficients with a P value
threshold for statistical significance of 0.01 to adjust for multiple
comparisons. We also assessed the correlation between GTVL and
anti-HIV activity as well as CVL microbicide and chemokine
levels using linear regression while adjusting for the PVL. We
conducted data analyses using GraphPad Prism (La Jolla, CA) and
STATA 9 (College Station, TX).
Results
Subject Demographic Characteristics
The 57 HIV-infected subjects not on antiretroviral therapy that
provided CVL samples for this study had diverse CD4 counts
(median 510 cells/ml, range 19–1,517 cells/ml), peripheral HIV
viral loads (median 4,650, range ,200–650,000 copies/ml) and
CVL HIV viral loads (median 400, range ,200–1,575,000 cop-
ies/ml). There were 30 subjects with CD4 counts .500 cells/ml,
21 subjects with CD4 counts 200–500 cells/ml, and 6 subjects with
CD4 counts ,200 cells/ml.
CVL from HIV-infected Women have Variable Anti-HIV
Activity Against X4 and R5-tropic HIV-1 Including
Transmitted/Founder (T/F) HIV-1 Strains
To determine whether CVL collected from 57 HIV-infected
women inhibit HIV infection of target cells, CVL were
incubated with either X4- or R5- tropic HIV-1 prior to the
measurement of HIV-1 infectivity via the TZM-bl assay. We
used seven different HIV-1 strains including two X4-tropic
viruses (IIIB and NL4.3), two R5-tropic/macrophage-tropic
viruses (BaL and Yu2.c) and three mucosally transmitted clade
B T/F viruses, CH058.c, CH077.c and RHPA.c, which can
utilize CCR5 co-receptor [20]. We observed that the median
values of anti-HIV activity of CVL samples varied widely (from
368% enhancement to complete inhibition) (Figure 1). Further-
more, among individual subjects we found a broad spectrum of
anti-HIV activity against any given HIV-1 strain ranging from
100% inhibition of viral replication to enhancement (,0%
inhibition) of viral infectivity of target cells.
Although T/F strain CH077.c and CH058.c were inhibited
comparably to the other reference strains, heterosexually-
transmitted RHPA.c was not as inhibited and also showed the
greatest propensity for enhancement of infection in the presence
of CVL. Overall, no single CVL sample showed clear inhibition
of all viral strains. Further, some CVL samples with substantial
activity against one HIV-1 strain exhibited substantially less
activity against a different HIV-1 strain, and there was no clear
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one viral tropism over another. Our data show that a broad
spectrum of HIV inhibitory activity against multiple strains
exists in the CVL of our cohort of HIV-infected women.
HIV Disease Progression Results in a Significant and
Selective Reduction of Intrinsic Anti-HIV Activity in CVL
We have shown previously that CVL from HIV-infected
women with CD4 counts .350 cells/ml exhibit intrinsic anti-
HIV activity [9]. In the current study we included HIV-infected
women with a broader CD4 count spectrum in the absence of
antiretroviral treatment: 30 had CD4.500 cells/ml, 21 had CD4
200–500 cells/ml and 6 had CD4,200 cells/ml. As seen in
Figure 2, we found a progressive loss of median anti-HIV activity
among women with lower CD4 counts against R5 tropic HIV-1
BaL, X4-tropic HIV-1 IIIB, and against the T/F strains CH058.c
and CH077.c. There was no significant loss of median CVL anti-
HIV activity for R5-tropic Yu2.c, and X4-tropic NL4-3. Overall
our data indicate that HIV disease progression is associated with
the loss of CVL anti-HIV activity against multiple HIV-1 strains.
Anti-HIV Activity in CVL does not Efficiently Inhibit
RHPA.c, a T/F Strain Derived from a Female Subject with
Heterosexual Transmission Risk
We recently reported the derivation of the T/F virus nucleotide
sequence from subject RHPA4259, and the generation of an
infectious molecular clone (IMC) RHPA.c [20]. RHPA.c repre-
sents the variant that established clinical infection in this female
subject who reported heterosexual transmission as her only risk
factor. In current study, we measured anti-HIV activity of CVL
from HIV-uninfected as well as HIV-infected women. Of the 15
HIV-uninfected samples, 12 could be tested for activity against
RHPA.c. As seen in Figure 3A, the majority inhibited this virus
with the exception of three samples, which showed a stimulatory
effect. Median percent inhibition in HIV-uninfected women was
36% (range 284% to 83%) whereas in 57 HIV-infected women,
the median percent inhibition was 8% (range 2368% to 93%;
Figure 3A). There was no significant difference in CVL anti-HIV
activity against RHPA.c between HIV-infected and HIV(2)
women as determined by a Mann-Whitney U test. Among HIV-
infected women, there was a trend toward lower CVL anti-
RPHA.c activity among women with CD4 counts ,200 cells/ml
compared to women with higher CD4 counts (Figure 3B). In fact,
of the 57 HIV-infected women, CVL from 19 (33%) enhanced
RHPA.c infectivity of TZM-bl target cells.
Association Between Peripheral HIV Viral Load (PVL) and
Genital Tract HIV Viral Load (GTVL) with Anti-HIV Activity
and Immune Parameters in the FRT
Recognizing that PVL is a key predictor of HIV disease
progression [16] and HIV transmission [27], and that GTVL is an
important determinant of viral shedding and secondary transmis-
sion in sero-discordant couples [28,29], we evaluated the
relationship between both PVL and GTVL and anti-HIV activity
(Table 1). The PVL correlated negatively with the magnitude of
anti-HIV activity against laboratory-adapted HIV-1 BaL and IIIB,
while there was no correlation between GTVL and CVL anti-HIV
activity either in univariate correlations or in multivariate linear
regression adjusting for the PVL. There were no correlations
between anti-HIV activity against laboratory-adapted X4 strain
NL4.3, R5 strain Yu2.c as well as R5 T/F strains CH077.c,
CH058.c, and RHPA.c and any of the clinical parameters (CD4
counts, blood/CVL viral load) measured (Table 1). The GTVL,
however, was higher among subjects with lower CD4 counts
(Spearman r 20.324, P=0.015) and correlated closely but
imperfectly with the PVL (Spearman r 0.3739, P=0.0049).
Figure 1. Broad and highly variable anti-HIV-1 activity of cervicovaginal lavage fluid from 57 HIV-infected women against multiple
R5 and X4 strains of HIV-1, including transmitted/founder viruses. Bars depict median, interquartile range and 95% confidence intervals.
Negative values indicate enhancement of infection.
doi:10.1371/journal.pone.0038100.g001
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Microbicides in the FRT
Previously, we and others demonstrated the presence of
endogenous innate anti-HIV factors in CVL [9,30,31,32] and
found that the levels of some antimicrobials correlated with anti-
HIV activity in healthy HIV-infected women [9]. We confirmed
these findings in the present study (data not shown). In the present
study, additionally, we measured HBD2, MIP-3a, SLPI, Elafin
and anti-HIV gp160 IgG in the CVL of HIV-infected women, and
evaluated correlations between levels of antimicrobials and subject
CD4 count, PVL, and GTVL (Tables 1 and 2). We found no
correlation between GTVL and CVL anti-HIV activity in
unadjusted analyses or when analyses were adjusted for the
PVL, but we did find significant positive correlations between
CVL levels of Elafin and SLPI and both the PVL and the GTVL
suggesting that some combination of immunodeficiency and
Figure 2. HIV disease progression exerts a selective impact on anti-HIV activity of cervicovaginal lavage fluid. HIV disease progression
to CD4 counts ,200 was associated with significant reductions in anti-HIV activity against the R5-tropic virus BaL (A) but not Yu2.c (B), on one of two
X4 tropic viruses IIIB and NL4.3 (C &D), and against both transmitted/founder (T/F) viruses CH058.c or CH077.c (E & F). Negative anti-HIV activity values
indicate enhancement of infection. Bars depict median, interquartile range and 95% confidence intervals; P values derived via Kruskal-Wallis tests.
doi:10.1371/journal.pone.0038100.g002
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mucosal defenses. The sole correlation between GTVL and the 14
measured cytokines/chemokines was with IL-1a (Spearman r
0.410, P=0.003), although this correlation was not evident in
unadjusted linear regression (correlation coefficient 20.002,
P=0.686) or linear regression adjusted for the PVL (correlation
coefficient 20.002, P=0.723).
HIV Disease Progression Exerts a Selective Impact on
Some Microbicides in CVL Fluid
Beyond identifying a correlation between the loss of anti-HIV
activity and antimicrobials in CVL and HIV disease progression,
we also found a significant and selective impact of HIV disease
progression on CVL microbicide levels (Figure 4). Lower CD4
counts were associated with lower CVL levels of HBD2 and a
trend toward lower CVL levels of MIP-3a. In contrast, lower CD4
cell counts were associated with higher levels of Elafin and SLPI in
CVL. These data suggest HIV disease progress results in a
profound but selective impairment in the multifaceted CVL
microbicide defense that parallels the selective loss of CVL activity
against multiple HIV-1 viral strains seen in Figure 1.
Predictors of Human CVL Cytokine and Chemokine
Responses and Anti-HIV Activity in HIV-Infected Women
To determine whether cytokines and chemokines present in the
CVL of HIV-infected women correlate with CD4, PVL, or
GTVL, we performed a 14-plex Luminex assay on CVL samples.
There were borderline significant correlations of the CD4 count
with the levels of two cytokines: MIP-1a (Spearman r 0.293,
P=0.039) and G-CSF (Spearman r 0.2822, P=0.047). We found
that the levels of only 3 effector molecules correlated weakly and
negatively with the peripheral HIV viral load: MIP-1a (CCL2;
Spearman r 20.318, P=0.028), MIP-1b (CCL3; Spearman r
20.321; P=0.025) and TNF-a (Spearman r 20.297, P=0.038)
whereas the majority of chemokines/cytokines exhibited no
correlation (data not shown). Of the 14 cytokines/chemokines,
13 correlated significantly with inhibition of at least 1 of the 7 viral
strains used for this study (Table 3). When correlations between 14
cytokines/chemokine with CVL anti-HIV activity were adjusted
Figure 3. Inhibition by cervicovaginal lavage of T/F virus RPHA.c derived from a woman who reported heterosexual intercourse as
her risk for contracting HIV. (A) There was no statistically significant difference between median values of inhibition of RPHA.c comparing women
with and without HIV infection. (B) Among HIV-infected women, HIV disease progression stage modulated the inhibitory effect of cervicovaginal
lavage fluid on RPHA.c. Negative anti-HIV activity values indicate enhancement of infection. Bars depict median, interquartile range and 95%
confidence intervals; P values via (A) Mann-Whitney U test and (B) Kruskal-Wallis test.
doi:10.1371/journal.pone.0038100.g003
Table 1. Correlations between CD4 count, peripheral HIV viral load and cervicovaginal HIV viral load with anti-HIV activity of
cervicovaginal lavage from HIV-infected women.
Viruses tested for anti-HIV activity CD4 count Peripheral HIV viral load Cervicovaginal lavage HIV viral load
Viral Tropism Virus N Spearman r P value Spearman r P value Spearman r P value
R5 BaL 57 0.647 ,0.001 20.347 0.009 20.178 0.189
Yu2.c 56 0.230 0.088 20.074 0.591 0.028 0.839
X4 IIIB 57 0.549 ,0.001 20.313 0.019 20.134 0.326
NL4-3 45 0.120 0.433 20.262 0.085 0.251 0.101
(T/F) CH058.c 51 0.245 0.083 20.033 0.823 20.052 0.718
Ch077.c 56 20.087 0.523 0.059 0.670 0.153 0.266
RHPA.c 47 0.021 0.888 20.130 0.389 0.043 0.778
CVL levels of the laboratory-adapted HIV viruses IIIB and BaL correlated positively with CD4 count and negatively with the peripheral HIV viral load. By contrast, there
were no significant correlations of CVL HIV viral load with anti-HIV activity against any virus.
doi:10.1371/journal.pone.0038100.t001
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putative anti-HIV microbicides in the cervicovaginal lavage of HIV-infected women.
CD4 count Peripheral HIV viral load Cervicovaginal lavage HIV viral load
Putative anti-HIV microbicide (pg/ml) N Spearman r P value Spearman r P value Spearman r P value
HBD2 56 0.046 0.732 20.003 0.984 0.226 0.094
Elafin 56 20.685 ,0.001 0.233 0.084 0.336 0.011
MIP-3a 56 0.232 0.082 20.128 0.347 20.012 0.931
SLPI 56 20.572 ,0.001 0.279 0.037 0.326 0.014
Protein 51 0.140 0.321 20.046 0.749 0.248 0.080
Anti-HIV gp160 IgG 41 0.215 0.177 20.035 0.829 0.174 0.283
Anti-HIV gp 160 IgG, normalized to CVL
protein
40 20.036 0.826 0.035 0.835 0.088 0.595
CVL levels of the putative endogenous anti-HIV microbicides Elafin and SLPI correlated negatively with the CD4 count, and positively with the CVL HIV viral load. By
contrast, the peripheral HIV viral load correlated positively only with CVL levels of SLPI and anti-HIV gp160 IgG.
HBD2, human beta defensin 2; Ig, immunoglobulin G; SLPI, secretory leukocyte protease inhibitor.
doi:10.1371/journal.pone.0038100.t002
Figure 4. HIV disease progression exerts a selective impact on putative anti-HIV microbicides in cervicovaginal lavage fluid. (A) CVL
levels of human beta defensin 2 (HBD2) were significantly lower among women with CD4,200 cells/ml. (B) CVL levels of Elafin were significantly
higher among women with CD4,200 cells/ml. (C) There was a trend toward lower CVL levels of macrophage inflammatory protein-3 alpha (MIP-3a)
among women with CD4,200 cells/ml. (D) CVL levels of secretory leukocyte protease inhibitor were higher among women with CD4,200 cells/ml.
Bars depict median, interquartile range and 95% confidence intervals; P values derived via Kruskal-Wallis tests.
doi:10.1371/journal.pone.0038100.g004
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Yu2.c activity became non-significant whereas all other correla-
tions trivially affected (data not shown). By contrast, the
significance of a subset of correlations between CVL cytokine/
chemokine levels and anti-HIV activity was altered after
adjustment for GTVL, suggesting that the relationships of
cytokines/chemokine levels to anti-HIV activity are impacted in
some instances by mucosal but not systemic virus. Specifically,
after adjustment for GTVL, linear regression correlation coeffi-
cients (CC) and P values, respectively, were: IL-1RA and RHPA.c,
CC 335.71, P=0.009; GM-CSF and IIIB, CC 0.20, P=0.007;
GM-CSF and Yu2.c, CC 0.26, P=0.002; GM-CSF and CH058.c,
CC 0.41, P,0.001; G-CSF and IIIB, non-significant (NS); G-CSF
and BaL, NS; RANTES and all anti-HIV activity, NS. The
heterosexually transmitted female T/F virus RHPA.c correlated
only with levels of IP-10. Interestingly, IL-1a did not show any
correlations with anti-HIV activity against any of the viral strains
but the sole correlation between GTVL and the 14 measured
cytokines/chemokines was with IL-1a (Spearman r 0.410,
P=0.003). Overall, these data suggest HIV disease progression
does not exert a major impact on the constitutive and multifaceted
cytokine and chemokine response in the FRT.
Discussion
The development of novel immunological means for preventing
the sexual transmission of HIV-1 is hindered by continuing
uncertainty regarding the critical mechanisms of immune defense
against HIV-1 transmission. Here, we show that CVL exhibits
both potent anti-HIV immune activity and a rich and multifaceted
content of cytokines, chemokines and endogenous microbicides,
with extensive correlation between the two and a clear and
selective impact of HIV disease progression on both. As a part of
these studies we found that HIV disease progression results in a
significant and selective reduction in intrinsic anti-HIV activity in
CVL, and that this loss of CVL anti-HIV activity is paralleled by
significant and selective disturbances in the CVL microbicide
content. Overall, these studies indicate that innate immune
protection in the FRT is compromised as women progress to
AIDS.
Although CVL exhibits broad anti-HIV activity against R5, X4
and T/F viruses [9], HIV disease progression impacts anti-HIV
activity of CVL differently for different viral strains. Specifically,
CVL anti-HIV activity against the laboratory-adapted isolate IIIB
and BaL as well as the sexually transmitted T/F viruses CH058.c,
CH077.c, and RHPA.c clearly declined with HIV disease
progression. No such pattern was observed for Yu2.c. or NL4.3.
Our data offer a possible explanation on why HIV-1 transmission
risk may increase with disease progression [33,34] and has
profound implications for the evaluation and development of
preventive measures that are active at all phases of HIV disease.
HIV disease progression was associated with specific alterations
in CVL immune responses. Levels of both Elafin and SLPI
correlated negatively with peripheral CD4 counts, suggesting
progressive elevations in these local inflammatory mediators
through the course of HIV disease progression. Both Elafin and
SLPI levels were correlated with PVL and GTVL, suggesting that
local and/or systemic antigen burden may be the prime
determinant of these non-specific but putatively protective
inflammatory responses. Importantly, the levels of all four putative
endogenous microbicides assessed – HBD2, Elafin, MIP-3a and
SLPI – were altered by HIV disease progression. To the best of
our knowledge, this is the first demonstration that innate immune
protection in the human FRT is lost as women with HIV-1
infection progress towards AIDS, and that this loss of anti-HIV
activity is mirrored by impairments in endogenous microbicides
such as HBD2. Other than impacting overall concentrations of
microbicides measurable by ELISA, the biological activities of the
molecules might be altered such as through protease digestion.
Many of the molecules we measured are expressed as precursor
proteins that must be cleaved for activation and/or release in
secretions by a spectrum of endogenous proteases, which are
present in FRT secretions [35,36]. For example, the cathepsin and
kallikrein families of proteases are present in FRT secretions and
can directly modulate the biological activities of a number of anti-
Table 3. Analysis of associations between the levels of cytokines and chemokines (CK/CC) with anti-HIV activity of the
cervicovaginal lavage (CVL) from HIV-infected women against the indicated viral strains.
Cytokine/chemokine IIIB NL4.3 Yu2.c BaL CH077.c CH058.c RHPA.c
IL-1a NS NS NS NS NS NS NS
IL-1RA 0.374, 0.008 0.414, 0.007 0.463, ,0.001 NS 0.390, 0.005 0.566, ,0.001 NS*
IL-6 0.438, 0.002 NS 0.433, 0.002 0.511, ,0.001 NS 0.524, ,0.001 NS
IL-8 NS 0.498, ,0.001 NS 0.376, 0.007 0.365, 0.009 0.405, 0.004 NS
IP-10 0.606, ,0.001 NS 0.502, ,0.001 0.463, ,0.001 NS 0.631, ,0.001 0.524, 0.007
MCP-1 (CCL2) NS NS NS NS NS 0.393, 0.005 NS
MIP-1a (CCL3) 0.560, ,0.001 NS 0.538, ,0.001 0.524, ,0.001 NS 0.501, ,0.001 NS
MIP-1b (CCL4) 0.448, 0.001 0.411, 0.007 0.387, 0.006 0.444, 0.001 NS 0.438, 0.002 NS
TNF-a 0.475, ,0.001 0.543, ,0.001 0.496, ,0.001 0.397, 0.004 NS 0.457, ,0.001 NS
GM-CSF NS* NS NS* NS NS NS* NS
G-CSF 0.456, ,0.001* NS NS 0.526, ,0.001* NS 0.420, 0.002 NS
RANTES (CCL5) 0.556, ,0.001* NS 0.501, ,0.001* 0.549, ,0.001* NS 0.563, ,0.001* NS
Eotaxin 0.548, ,0.001 NS 0.456, ,0.001 0.419, 0.003 NS 0.458, ,0.001 NS
Fractalkine (CX3CL1) 0.495, ,0.001 0.488, 0.001 0.545, ,0.001 0.454, ,0.001 0.367, 0.009 0.537, ,0.001 NS
Numbers in cells indicate r value for Spearman correlation and P value, unless P value for correlation is .0.01 in which case correlation is listed as not significant (NS).
*Significance of correlation altered by adjustment for GTVL (see text for details).
doi:10.1371/journal.pone.0038100.t003
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[37,38,39]. Since ELISA assays measure levels but not biological
activity of anti-HIV molecules, this could be an explanation for
enhanced susceptibility of some women but not others.
The levels of nearly all 14 cytokines and chemokines we
measured correlated significantly with CVL anti-HIV activity, but
not with HIV disease progression. Notably, no single cytokine or
chemokine correlated with anti-HIV activity against all tested viral
strains. While these data suggest that the maintenance of robust
and multifaceted immune responses are important to innate
immune protection against HIV and other sexually transmitted
pathogens, they do not identify a single mechanistic explanation
for the clear and documented CVL anti-HIV activity. It will be a
high priority to test the impact of blocking chemokines and
cytokines individually and in combination on CVL anti-HIV
activity against an expanded panel of relevant reference and T/F
viruses. This approach will allow us to identify which inflamma-
tory mediators are most critical to immune protection from HIV-1
transmission and thus candidates for novel combination topical
approaches to transmission reduction.
Systemic and mucosal HIV viral loads were major drivers of
CVL levels of the immune mediators Elafin, SLPI and IL-1a.I n
addition, correlations between a subset of CVL cytokines/
chemokines with anti-HIV activity, including those with GM-
CSF, G-CSF and RANTES, were altered after adjustment for
GTVL but not PVL by linear regression. This suggests but does
not prove that some mucosal immune responses are preferentially
impacted by the presence of virus at mucosal surfaces. By contrast,
the levels of most measured endogenous antimicrobials, cytokines
and chemokines were either constitutive or driven by the presence
of alternate (non-HIV) pathogens. Given the known association
between both sexually transmitted infections and bacterial
vaginosis with the risk of sexual transmission of HIV-1 [40,41],
it will be critical to identify the modifiable drivers of the levels of
innate immune mediators in CVL and their impact on CVL anti-
HIV activity.
By relating the broad anti-HIV activity of CVL with HIV
disease progression and multiple innate immune responses, these
studies provide a framework for future investigations into the
mechanisms of innate immune protection against HIV that can be
used in the development of novel approaches to prevent the sexual
transmission of HIV-1. Although the immune responses we
measured in the CVL likely constitute the first line of immune
defenses against HIV-1, other mucosal immune responses also
avert HIV-1 transmission and were not assessed in this study.
None of our subjects were on antiretroviral therapy, which is
essential to determine intrinsic anti-HIV activity of CVL.
However, this study design precludes assessment of a different
yet important question: the impact of ART on CVL anti-HIV
activity or innate immune responses. We hypothesize ART will
simultaneously boost anti-HIV activity while reducing the local
and systemic inflammatory triggers for the release of putative anti-
HIV mediators like Elafin and SLPI.
As we showed previously [9], some CVL samples inhibit,
enhance, or have no effect on HIV infection of target cells
depending upon the viral strain used. FRT secretions contain a
multitude of innate immune mediators that fluctuate with the
menstrual cycle [31,42]. For instance, CVL levels of HBD1,
HBD3, HBD4, SLPI, and Elafin all peak during different stages of
the cycle [30,43,44,45]. Previously, we found that these changes
are due to sex hormones in that SLPI and HBD2 are regulated by
estradiol [46,47]. Thus, one possible explanation for the variability
of activity against different viral strains is that subject samples were
collected independent of menstrual status. However, in other
cases, we found that a given CVL sample with potent activity
against one HIV strain had no activity against others. This finding
suggests that different molecules in CVL have differential
biological activity against different strains of HIV, indicating that
the overall anti-HIV activity of a given CVL sample is determined
by synergistic or antagonistic interactions between CVL innate
immune factors, most likely due to the changing hormonal milieu
of the menstrual cycle. Our data reflect only one clade B T/F virus
from a female subject who likely acquired HIV through
heterosexual transmission. Future studies with a greater variety
of T/F viruses, and with an array of R5 and X4 viruses, will be
important to determine if T/F viruses from different transmission
mechanisms and with different cellular tropisms exhibit differential
abilities to elude innate immune protective responses. We suspect
it is unlikely there is a single factor responsible for anti-HIV
activity in FRT secretions, and rather that it will be most
important for the development of novel immunological strategies
for the topical prevention of HIV-1 transmission to identify the
factors most predominantly and commonly prevent transmission
when acting in concert.
In conclusion, our data depict the multifaceted innate immune
responses in CVL against HIV-1, and newly establish that these
factors are not only selectively impacted by HIV disease
progression and only partly impacted by local and systemic HIV
infection. Understanding the impact of this multifaceted mucosal
defense system against a wide array of HIV-1 strains including T/
F viruses will aid the development of novel approaches to the
combined topical prevention of HIV-1 transmission. It will be
particularly critical to harness key innate immune mediators that
contribute to CVL anti-HIV activity despite HIV disease
progression.
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